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Abstract
Vertigo and dizziness are amongst the most common symptoms in medicine and often have a major impact on activities 
of daily life. Although many causes of vertigo and dizziness can easily be recognized, patients often receive inappropriate 
and ineffective treatment. The reasons for this are various. Because vertigo/dizziness is an interdisciplinary symptom and 
there is a lack of standardised diagnostic tools, it is easy to lose the overview of the possible differential diagnoses. There is 
evidence though, that the management of patients with vertigo/dizziness can be optimized using standardized care pathways 
with digital support. The present study (within the framework of “PoiSe—prevention, online feedback, and interdisciplinary 
therapy of acute vestibular syndromes by e-health”) aims to evaluate the implementation of a program with several interlock-
ing components. The three main components are a computerized clinical decision system, a mobile application, a counselling 
and interdisciplinary educational program developed by the German Center for Vertigo and Balance Disorders (DSGZ). The 
study is a cluster-randomized controlled trial with a parallel-group design, as well as a detailed process evaluation. Clusters 
comprise of primary care physician practices in Bavaria, Germany. In the scope of the study the effectiveness, acceptability 
and efficiency of the intervention will be evaluated. It is anticipated that the intervention will improve the quality and effi-
ciency of the management of dizzy patients. A higher diagnostic accuracy, optimized treatment, and disease progression 
monitoring is expected to improve patient-relevant outcomes and reduce health-care costs.
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Background
Vertigo and dizziness are amongst the most common key 
symptoms in medicine. Lifetime prevalence has been 
shown to lie between 20 and 30% [1, 2]. Claims data 
from the Bavarian Statutory Health Insurance Physicians’ 
database showed that over 9% of the adult population 
received a diagnosis of vertigo annually, most of these 
in primary care [3]. Disorders of the central or peripheral 
vestibular system may lead to severe permanent disability 
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or to considerable restrictions of daily life [4]. Although 
most syndromes—as a rule—can be correctly diagnosed 
and managed by specialists with interdisciplinary train-
ing [5], there is still a large discrepancy between recom-
mended and actual management of patients with vertigo 
[6, 7]. This might lead not only to overuse of health care 
resources [4, 8], but also to a prolonged clinical course 
and to the development of chronic complaints or somatiza-
tion. Notably, primary care physicians perceive diagnosis 
and treatment of vertigo as complex and challenging while 
they feel that they risk missing life-threatening conditions 
such as stroke or neoplasms [7]. Also, while monitoring 
symptom evolution under treatment, which is of the utmost 
relevance for the disease management, it has been noted 
that the resources of a typical primary care consultation 
are too limited to closely monitor patients with vertigo. 
Likewise, the narrow view of single aspects of the under-
lying disorders reflects the compartmentalization of the 
clinical specializations (neurology, otorhinolaryngology, 
internal medicine, etc.) with non-uniform clinical guide-
lines, and insufficient interdisciplinary cooperation [9].
To overcome these problems of management, monitoring 
and lack of interdisciplinary consultation, various comput-
erized solutions have been proposed. Computerized clini-
cal decision support systems (CCDS) are technologies that 
aim to optimize clinical decision-making in situations of 
uncertainty and complexity [10]. Evidence for their effec-
tiveness has been shown for care process parameters such as 
the ordering of diagnostic tests [11] or medication prescrip-
tion. Evidence for their effectiveness on patient-reported 
outcomes, however, is still limited [12]. Secondly, various 
mobile solutions for the management of chronic disease and 
risk factors, e.g. for type 2 diabetes [13], bipolar disorders 
[14], headache [15] or congestive heart failure [16] that have 
the potential to facilitate monitoring therapy adherence and 
success are currently being developed. Thirdly, in remote 
rural areas tele-medicine applications are increasingly used 
to support primary care decisions with expert advice (e.g. 
in stroke [17] or emergency medicine [18]; for review see 
[19]). All these solutions are often implemented as isolated 
interventions without overarching concept of care and with-
out dedicated evaluation of the implementation processes 
and their barriers.
We therefore hypothesized that a combination of CCDS 
with an easy-to use mobile application and systematic expert 
support would be able to improve diagnostic accuracy and 
outcomes of patients presenting with acute vertigo syn-
dromes in primary care, if supported by a large network of 
different stakeholders.
The objective of this study is therefore to evaluate the 
implementation of an innovative program with several inter-
locking components. Specifically, we want to examine the 
effectiveness, acceptability and efficiency of the new pro-
gram in primary care.
Methods
The study protocol follows the Standard Protocol Items: 
Recommendations for International Trials (SPIRIT).
Trial design
The present study is a cluster-randomized controlled trial 
with a parallel-group design (PG-CRCT), including a 
6-month pilot phase. A detailed process evaluation along-
side the trial will be carried out.
Clusters will be primary care practices in Bavaria, one 
of Germany’s 16 federal states with a population of about 
13 millions. Clusters will be randomly assigned in a bal-
anced 1:1 block design to either the intervention or the 
control group after inclusion into the main study. Con-
cealed allocation of participating practices will be imple-
mented centrally by an independent person that has no 
knowledge of the practice identity. The randomization 
sequence will be computer-generated. The size of the 
practice (number of patients per year) will be considered 
as a stratification factor. Practices with special focus on 
vestibular or balance disorders will be excluded.
The study will be submitted to the local ethics commit-
tee for approval and prospectively registered in the Ger-
man Clinical Trials Register (DRKS) before inclusion of 
the first patient.
Participants
Clusters Practices in Bavaria will be eligible if they 
are led by at least one primary care physician and have 
patients insured by the Allgemeine Ortskrankenkasse Bay-
ern (AOK Bayern), one of the largest health insurance 
funds in Bavaria with approximately 4.5 millions insured 
patients. As insured patients are entitled to freely choose 
their physician and some patients might directly consult 
medical specialists, neurologists, otorhinolaryngologists 
and internal medicine specialists will be included in addi-
tion to family practitioners.
Patients Consenting patients will be eligible for inclu-
sion if they newly consult a participating practice for acute 
vertigo or dizziness (ICD-10 codes (H81.1–H81.3, H81.8, 
H81.9, R42 with G63, E53.8, N95.1, G62, I951, H55 or 
F45.8), are at least 18 years old, and are mentally able to 
follow instructions. They must also be insured by the AOK 
Bayern. Patients will be excluded if they are suffering from 
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a mental illness (e.g. dementia), or a terminal disease with 
a life expectancy of less than 12 months.
Intervention
The intervention consists of three basic components: a 
web-based platform (CCDS), a mobile application, and a 
structured system for continuing medical education, expert 
support and auditing (see Fig. 1).
Patients presenting with acute vertigo at the physician’s 
office will be eligible for inclusion in the study. After inclu-
sion, the physician (family practitioner, neurologist, otorhi-
nolaryngologist, internal specialist) will use the CCDS. 
The patient’s answers to a few basic questions (e.g. How 
long does the vertigo last?), symptoms (e.g. vomiting) and 
clinical findings (e.g. horizontal nystagmus) will be analysed 
by an AI-based algorithm. Subsequently suggestions are 
offered to the physician for a) a categorization of the possi-
ble underlying syndrome (e.g. peripheral vs. central vertigo), 
b) required diagnostic procedures, c) treatment options, and 
d) referral to physicians with a different medical speciality 
(e.g. referral from a family practitioner to a neurologist). 
Additionally, the physician will receive a warning message 
when symptoms of a severe underlying disease are noted 
(e.g. skew deviation in cerebral stroke).
Questionnaires and underlying decision algorithms are 
based on national and international guidelines and the Inter-
national Classification of Vestibular Disorders (ICVD) of 
the Bárány Society.
After the diagnostic process has been completed, the 
patient is given access to a mobile application (app). This 
application informs the patient about the underlying disease, 
supports the therapeutic process and monitors the course of 
the disease. The app is personalized to the patient’s demo-
graphic data (age, gender, language, visual impairment) and 
to the diagnosis. Furthermore, patients will be instructed to 
fill out a vertigo/dizziness diary on a daily basis. A newly 
developed, AI-based algorithm then monitors the informa-
tion gathered from the diary and correlates it with the indi-
vidual disease. Additionally, an integrated video documen-
tation and analysis system will analyse eye movements and 
gait abnormalities by the means of pattern recognition (e.g. 
neuronal networks, deep learning algorithms) [20–22]. It 
will be used to objectify the diagnosis and classify patient’s 
self-recorded symptoms.
In case of an unwanted outcome, e.g. signs of a somatiza-
tion disorder or no visible improvement of symptoms, the 
app informs the patient and the physician about this devel-
opment and suggests that the diagnosis and treatment be 
reconsidered. The physician additionally has access to an 
expert network for further support.
The expert network will be established throughout the 
study period. Physicians with special interest in vestibular 
disorders, taking geographic criteria into consideration, 
will be selected to participate in interdisciplinary profes-
sional training sessions, video-based case review sessions 
and consultations by phone. The aim is to create a broad 
network of physicians that are able to correctly diagnose and 
treat patients with vertigo/dizziness using an interdiscipli-
nary approach. This is especially relevant for rural areas or 
regions with a sparse medical network. The expert network 
overall is intended to complement the digital solution.
The anticipated contents of the three main components 
are summarized in Fig. 2. The intervention will be tested in 
a 6-month pilot period. Adaptations of the intervention and 
the contents after this time-period are possible (see below).
Fig. 1  Summary of the process 
flow of the intervention. During 
the study period the German 
Center for Vertigo and Balance 
Disorders (DSGZ) will re-assess 
all patients for the purpose of 
validating the diagnosis and 
treatment. Further, the expert 
network will be established 
throughout the study period
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Data collection procedures
Data will be collected at physician (cluster) and patient level. 
Patient data will be collected at inclusion and after 3 and 
6 months. After three months, all patients will be invited to 
be re-assessed at the German Center for Vertigo and Balance 
Disorders (DSGZ; see Fig. 1), an outpatient tertiary univer-
sity unit specialized in the diagnosis and treatment of vertigo 
and balance disorders. Re-assessments will be blinded to the 
initial diagnosis and to the study group. Data management 
will follow the General Data Protection Regulation.
Measures
The outcomes were chosen to measure the effectiveness, 
acceptability and efficiency of the intervention at provider 
(cluster) and patient level.
To measure effectiveness at the provider level, the accu-
racy of diagnoses made by the primary care physician will 
be evaluated by re-assessment at the DSGZ. Primary effec-
tiveness outcomes at the patient level will be measured 
using the Dizziness Handicap Inventory (DHI), a validated 
instrument for measuring disease-specific quality of life and 
participation in social life [23]. The DHI scores between 0 
and 100, with higher scores indicating a decrease in quality 
of life. Generic quality of life will be measured using the 
EuroQol-5D (EQ-5D) [24].
The acceptability and feasibility of the intervention will 
be assessed using a mixed methods approach. Qualitative 
data will be ascertained by purposeful sampling through 
individual and group interviews [25]. Quantitative data will 
be gathered by questionnaires and standardized documen-
tation of the processes throughout the entire study period 
(including access data generated from the web-platform and 
the mobile application).
Efficiency will be assessed in terms of the utilization of 
health care services and the respective costs. To this end, 
routine data provided by the health insurer AOK Bayern 
will be linked to individual patient data from the trial. We 
will concentrate on outpatient visits, hospitalizations, visits 
to the emergency room, and imaging, because these seem to 
be the major cost drivers [26].
Process evaluation
Process evaluation will be conducted according to the guide-
lines of the Medical Research Council (MRC) Framework 
for evaluating complex interventions [27]. During an ini-
tial 6-month pilot period, the acceptance and feasibility of 
the intervention and its components will be evaluated using 
a mixed-methods approach. In the following main trial 
(16 months of recruitment of patients) the processes and 
quality of the implementation will be evaluated. We will 
Fig. 2  Contents of the three 
main components of the 
intervention: the web-platform 
with the CCDS, the mobile 
application, and the educational/
support system
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evaluate various aspects, including the structure and per-
formance of the included practices, implementation fidel-
ity, satisfaction with the intervention and implementation, 
assessment of scalability, and documentation and assess-
ment of unexpected effects. Auditing will include quality 
parameters such as study protocol adherence and number 
of protocol violations, data quality, and adherence to data 
protection protocols.
Harms
The intervention is not expected to lead to any adverse 
events. Serious unexpected effects believed to be related to 
the intervention will be collected and recorded according 
to the GCP from randomization of the first patient through 
90 days after the inclusion of the last patient. In this case 
the intervention will be discontinued, and the patient will 
be referred to a medical expert.
Sample size
A difference of 6–10 points in the DHI with a standard 
deviation of 20 points is assumed to be a relevant clinical 
difference. This corresponds to an effect size of between 
0.3 and 0.5 [6]. A two-sided t-test for independent groups 
with an effect size of 0.3, an alpha of 0.05 and beta of 
0.20 (power = 80%) results in a sample size of n = 352 
individuals. The inclusion of 10 patients per cluster was 
assumed with a drop-out rate of 10%, which corresponds 
to the drop-out rate of similar studies [28, 29]. Therefore, 
the inclusion of nine patients per cluster was assumed. 
Taking into account a conservative inter-cluster correla-
tion coefficient (ICC) of 0.04 [30], a design effect (DE) of 
1.32 was calculated (DE = 1 + (k – 1)  × ICC). This results 
in a sample size of n = 468 patients (234 in the interven-
tion program and 234 in the standard care) and thus 52 
clusters. At the level of the clusters, a drop-out rate of 2 
clusters per study arm can be expected [31]. To further 
compensate for possible variations in patient recruitment 
of the clusters, two additional clusters per study arm were 
considered. Thus, a total of 60 clusters with 600 patients 
was calculated.
The additional 6-month pilot phase will include 10 clus-
ters with an expected recruitment of 10 patients per cluster 
(total n = 100 patients; 50 for each study arm). The aim of 
the pilot phase is to gather information to optimize the study 
processes (recruitment, randomisation, data gathering, etc.) 
and to adapt/improve the CCDS and mobile application. The 
measured outcomes of the pilot phase will not be included 
in the evaluation and statistical analysis of the main study.
Discussion
We expect that the intervention will improve the quality and 
effectiveness of the management of patients presenting with 
acute vertigo or dizziness.
The intervention is expected to optimize the diagnostic 
decision process, thus, leading to a timely and more effec-
tive therapy and a relevant improvement of patient-relevant 
outcomes. Also, the mobile application will facilitate treat-
ment adherence and symptom management.
Potential limitations that have to be considered include 
issues of acceptability and usability of the mobile applica-
tion and interoperability of the web solution. Special needs 
of persons with disabilities and older persons will have to 
be considered. This increased diagnostic accuracy and opti-
mized treatment has the potential to improve long term out-
comes and reduce health-care costs by reducing the number 
of diagnostic procedures, the number of consultations, and 
the treatment costs.
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